1. Introduction {#sec0005}
===============

Oral cancer accounts for approximately 2.1% of all cancers worldwide, with an estimated 300,000 new cases and 145,000 deaths in 2012 [@bib0005]. Moreover highest mortality rates (77%) occurred in the developing countries. In India, oral squamous cell carcinoma (OSCC) is the most common cancer with half a million new cases diagnosed every year [@bib0010]. It is more common in males with a large fraction of cases typically diagnosed in late stages and are usually treated by chemoradiation [@bib0015]. Prognosis is still relatively poor and has shown only slow progress with 5-year actuarial survival rates between 30% and 40% in most of the studies [@bib0020]. Patients in advance stage usually presents with multiple cervical lymph node metastasis, which further decreases the 5-years cancer specific survival by 50% when compared with node negative patients [@bib0025]. Despite of significant improvement achieved during the last decades in its detection, prevention and treatment; outcome and prognosis related to cure and survival have still been poorer due to tragic event of treatment resistance and tumor recurrence. More than 50% of patients eventually develop local recurrence or metastasis usually within the first 2 years following completion of treatment [@bib0030].

Prognosis and treatment outcome is certainly influenced by stage, tumor grade, site, depth of invasion, lymphovascular spread, patient's age, and performance; however it has been found that in same stage disease, response to treatment varies with individual, might be due to variation in tumor biology related to cell morphology or genetic phenotype of the tumor [@bib0035]. Therefore heterogeneity of tumor cells introduces significant threat in the management of OSCC. Recent advances in molecular biology field and improved conception of the pathogenesis of OSCC have provided access to many new orientations to the research in this direction. The molecular markers of concern are those involved in cell cycle regulation and cell signaling pathway. Oncogenes which promote cell and tumor growth includes growth factor receptors (hst-1, int-2, EGFR/erbB,c-erbB-2/Her-2,sis), intracellular signal transducer (ras,raf,stat-3), transcription factors (myc, fos, jun, c-myc), cell-cycle regulators (Cyclin D1), apoptosis regulatory protein (bcl-2,bax) & tumor suppressor gene (p53, Rb) which encodes proteins that typically transduce negative growth regulatory signals; these have been identified as genetic alterations in each of the pathological stages of OSCC [@bib0030]. Out of these, Cyclin D1, EGFR and p53 gene have emerged as exquisitely critical mediators in the pathogenesis of OSCC. Activation of Cyclin D1, p53, EGFR are known to be inhibitors of apoptosis and play crucial role in initiation of intracellular signaling pathways which regulate the activation of cell proliferation, invasion, angiogenesis and metastasis and thereby influence treatment outcome Expression of these proteins have also been correlated with a more aggressive phenotype and worse prognosis. Therefore, quantification of the activation status of these markers would be a potential parameter for predicting treatment outcome \[[@bib0040], [@bib0045], [@bib0050]\]. Association of these markers with treatment response and survival have been examined in many studies, but very few studies have correlated the expression of these markers with tumor recurrence, which is a major concern in OSCC \[[@bib0055], [@bib0060]\]. Most of the work has been done in other malignancies like breast, lung, colorectal, bladder and Gastrointestinal tract \[[@bib0065], [@bib0070], [@bib0075], [@bib0080], [@bib0085]\]. Owing to most feared malignancy due to its aggressive nature and high mortality rate, there has been a constant search for new prognostic and predictive markers so as to understand the tumor behaviour, treatment outcome and tendency to recur. Search for the new markers might be considered as an emerging approach to individualize and facilitate treatment planning by categorizing patients according to risk factors detected, so that high risk patients might be kept under aggressive surveillance for the assessment of disease relapse.

We have therefore conducted this study with the objective to assess the association of expression of Cyclin D1, EGFR and p53 with recurrence and pattern of recurrence in OSCC patients undergoing chemoradiation.

2. Materials and methods {#sec0010}
========================

Total 290 histologically proven new cases of locally advanced stage (III, IV, M0) oral cancer with World Health Organization (W.H.O.) performance status (PS) of grade 0/1 attending radiotherapy O.P.D, in the year 2009--2012 were enrolled in the study. These cases were assessed thoroughly (history, clinical examination and investigations). The study was approved by the ethics committee of the Institution, and written informed consent was obtained from all patients before enrollment. All the patients were given 2-cycles of induction taxol (175 mg/m^2^ day 1) and cisplatin (50 mg/m^2^ day 2) chemotherapy and were subjected for radiation along with concurrent cisplatin (35 mg/m^2^) 4-weeks from completion of induction chemotherapy. Radiotherapy was given by External beam Conventional Method (200CGy/fraction to a total dose of 70 Gy in 35 fractions in 7-weeks by cobalt^60^ to primary tumor site and neck. The protocol plan was continued despite mucositis or dermatitis. However, the dose of cisplatin was reduced to 50% if the calculated creatinine clearance level was 30--50 ml/min. No cisplatin was given if the creatinine clearance level was less than 30 ml/min. In presence of myelosupression (WBC count \< 4000/mm^3^ or platelets count less than 100,000/mm^3^), persistent fever that exceeded 38 °C or other clinically apparent infections, chemoradiation was postponed for 1-week or interrupted.

For histopathological and immunohistochemical studies, tumor samples from the lesion site was fixed in 10% buffered formalin and then embedded in paraffin. Paraffin embedded formalin fixed tissues were processed routine H & E stained sections evaluated to confirm the diagnosis of squamous cell carcinoma and to grade the lesion. Further sections were processed for Cyclin D1, EGFR and p53 biomarkers by immunohistochemistry (IHC) using primary monoclonal antibodies and a polymer based secondary antibody detection kit from Dakopatts, Denmark. Standard Immunohistochemistry protocol was used. In short deparaffinized rehydrated sections were blocked for endogenous peroxidases in 0.3% hydrogen peroxide in methanol, followed by a rinse in distill water. Antigen retrieval was achieved at 121 °C in 10 mM citrate buffer (pH 6.0) for 10 minutes using Pascal retrieval system from Dakopatts, Denmark. Slides cooled to room temperature were washed thrice with TBS and thereafter incubated overnight at 4 °C with Primary Antibdies to Cyclin D1 (Dakopatts Denmark), p53 (DO7, Leica Microsystems, Germany) and EGFR (BioGenex, USA). After washing with Tris-buffered saline, the sections were incubated for 30 minutes with secondary antibody. The Cyclin D1, EGFR and p53 were visualized with DAKO Liquid Diaminobenzidine substrate chromogen and counterstained with diluted Mayer's haematoxylin. Sections mounted with DPX were inspected under a Zeiss Z2 imager and photographed at 40X magnification. The immunohistochemical evaluation was carried out in tumor hotspots including the invasion front, which was regarded as most indicative of the biological activity of the tumor, in 10 high power fields. About 1500--2000 tumor cells were observed in all tumors at a magnification of 40X in 10 selected fields. For Cyclin D1 and EGFR tumors were labeled as negative if \<10%, moderate positive between 10--50% and strongly positive if \>50%, tumor cells expressed the antigen \[[@bib0090], [@bib0095]\]. The p53 expression was evaluated as negative if \<10%, moderate positive between 10--25% and strongly positive if \>25% \[[@bib0100]\].

Assessment of tumor response was done by clinical examination, radiological investigations (CT-scan) 4--6 weeks after completion of treatment. Biopsy or fine needle aspiration cytology to determine pathological response was not performed routinely; it was done only in case of recurrent disease/partial response of the clinically and radiologically suspected lesion to confirm the presence of disease. The definitions of treatment response viz. complete response (CR), partial response (PR) and no response (NR) \[stable disease (SD) + progressive disease (PD)\] were based on the standard definitions established by W.H.O. (1979). After chemoradiation, patients were followed up to 2-years and were assessed for the recurrence and survival.

The primary end measures of the study was to assess the association of expression of Cyclin D1, EGFR and p53 with recurrence, time to recurrence and type of recurrence in OSCC patients undergoing chemoradiation. The secondary end point of the study was 2-years survivals (overall, disease free and recurrence free). Survival time was defined as the interval between the date of initial treatment and the date of the last follow up examination.

2.1. Sample size determination {#sec0015}
------------------------------

The sample size and power the test statistics of present study is based on complete response followed by recurrence within 2 years in OSCC patients undergoing chemoradiation. Expecting at least 25% recurrence within two year after complete response in OSCC patients undergoing chemoradiation and considering 5% margin of error (type I error: α = 0.05) and 80% power (type II error: 1-β = 0.80), minimum 290 patients will be required for the study is evaluated [@bib0105] as below:$$\begin{matrix}
n & = & \frac{t \times t \times p(1 - p)}{e^{2}} \\
 & = & \frac{1.96 \times 1.96 \times 0.25(1 - 0.25)}{0.05^{2}} \\
 & = & 288.12 \\
 & \approx & 290 \\
\end{matrix}$$where,

n = sample size

t = confidence level of t statistic at 95%, standard value = 1.96

p = effect size = 25%

e = margin of error = 0.05%

Thus, a minimum 290 patients will required to get at least 25% recurrence in OSCC patients undergoing chemoradiation.

2.2. Statistical analysis {#sec0020}
-------------------------

Continuous data were summarized as Mean ± SE (standard error of the mean) while discrete (categorical) in number and percentage. Continuous groups were compared by Student's t-test or one way analysis of variance (ANOVA) followed by Tukey's post hoc test whereas applicable. Categorical groups were compared by chi-square (χ^2^) test. Pearson correlation analysis was also done to asses association between the variables. Binary logistic regression analysis was done to assess association and risk predictors of recurrence. Cox-regression analysis was done to find out independent predictors of overall survival and recurrence. Survival between groups was done by Kaplan-Meier method followed by Log rank (Mantel-Cox: χ^2^) test. A two-tailed (α = 2) *P* \< 0.05 was considered statistically significant.

3. Results {#sec0025}
==========

3.1. Clinico-pathological characteristics {#sec0030}
-----------------------------------------

The clinico-pathological characteristics of 290 OSCC patients are summarized in [Table 1](#tbl0005){ref-type="table"}. The age of patients ranged from 20--67 years with mean (± SE) 50.49 ± 0.69 years and median 53 years. Most of the patients were ≤60 yrs (75.9%), mostly males (79.7%) and mostly belongs to poor socio-economic status (59.3%). Out of total, 66.2% patients had tobacco chewing habit, 62.4% had betel nut chewing habit and 55.9% had smoking habit. At initial presentation, the PS of 43.1% patients was poor. Further, in patients, buccal mucosa was the most common primary site (32.1%) followed by tongue (16.6%), alveolus (15.5%), retromolar trigone (RMT) (13.4%), hard palate (13.1%) and lip (9.3%). Moreover, histology of most of the patients was invasive squamous cell carcinoma (ISCC) (64.8%), grade well differentiated (67.2%), tumor size T4 (75.5%) and stage IV (78.6%). The radiological response of 44.1% patients was complete (CR), 46.6% was partial (PR) and 9.3% had no response (NR) accounting 90.7% responders (CR + PR).

3.2. Marker expressions {#sec0035}
-----------------------

The Cyclin D1, EGFR and p53 protein expressions of OSCC patients were done using IHC ([Fig. 1](#fig0005){ref-type="fig"}) and quantified in percentage(%) and sub grouped into three groups (negative, positive and strong positive) ([Table 2](#tbl0010){ref-type="table"}). The Cyclin D1, EGFR and p53 expression of patients ranged from 0--90%, 0--90% and 0--86% respectively with mean (± SE) 40.69 ± 1.29%, 51.33 ± 1.43% and 43.35 ± 1.38% respectively and median 40.0%, 50.0% and 48.0% respectively. According to Cyclin D1 expression, 31 (10.7%) patients were negative, 197 (67.9%) were positive and 62 (21.4%) were strong positive. The EGFR expression showed 13 (4.5%), 135 (46.6%) and 142 (49.0%) respectively and p53 expression showed 35 (12.1%), 46 (15.9%) and 209 (72.1%) respectively. On correlating the quantitative expressions, the Pearson correlation analysis showed significant and positive correlation between the marker expressions (Cyclin D1 vs. EGFR: r = 0.71, *P* \< 0.001; Cyclin D1 vs. p53: r = 0.73, *P* \< 0.001; EGFR vs. p53: r = 0.86, *P* \< 0.001).

3.3. Diagnostics of markers {#sec0040}
---------------------------

### 3.3.1. Association of marker expressions with clinico-pathological characteristics {#sec0045}

To find out diagnostic significance of markers, the association between marker expressions (negative/positive/strong positive) and clinico-pathological characteristics was done using χ^2^ test ([Table 3](#tbl0015){ref-type="table"}). The χ^2^ test showed significant (*P* \< 0.05 or *P* \< 0.01 or *P* \< 0.001) association of Cyclin D1 expressions with performance status, histological grade, tumor size, node status, stage and radiological response. In contrast, EGFR expressions showed significant (*P* \< 0.05 or *P* \< 0.01 or *P* \< 0.001) association with socio-economic status, histological grade, node status, stage and radiological response. Conversely, p53 expressions showed significant (*P* \< 0.05 or *P* \< 0.01 or *P* \< 0.001) association with age, performance status, primary site, histological grade, tumor size, node status, stage and radiological response. Further, multivariate logistic regression analysis showed that the tobacco chewing, histological grade, tumor size, node status and stage were significant (*P* \< 0.05 or *P* \< 0.001) and an independent predictors of Cyclin D1 expressions ([Table 4](#tbl0020){ref-type="table"}). In contrast, histological grade and node status were found significant (*P* \< 0.01) and an independent predictors of EGFR expressions ([Table 4](#tbl0020){ref-type="table"}). Conversely, age, tobacco chewing, betel nut chewing, primary site, histological grade, tumor size, node status and stage were found to be the significant (*P* \< 0.05 or *P* \< 0.01) and independent predictors of p53 expressions ([Table 4](#tbl0020){ref-type="table"}).

### 3.3.2. Association of marker expressions with recurrence, site and type of recurrence {#sec0050}

The patients were followed-up for 2 years (24 month). The survival duration of patients ranged from 1--24 month with mean (± SE) 10.84 ± 0.39 months and median 9 months. During the period, 210 (72.4%) patients were alive, 32 (11.0%) lost to follow-up (LTF) and 48 (16.6%) died due to disease accounting total 242 (83.4%) patients live (alive + LTF). Further, at final evaluation, 128 (44.1%) patients were disease free (i.e. CR) of which 56 developed recurrence during the two-years follow-up and thus the prevalence of recurrence being 43.8% or in other words 234 (80.7%) patients were recurrence free. Of total recurrence, 47 (83.9%) had locoregional and 9 (16.1%) had distant recurrence. Further, 3 (5.4%) had recurred in bone, 1 (1.8%) had in brain, 5 (8.9%) had in lung, 31 (55.4%) had in nodal and 16 (28.6%) had in primary. The association of marker expressions with recurrence, site and type of recurrence is also analyzed and summarized in [Table 5](#tbl0025){ref-type="table"}. On correlating, χ^2^ test showed significant (*P* \< 0.05 or *P* \< 0.01 or *P* \< 0.001) association of marker expressions (Cyclin D1, EGFR and p53) with recurrence. The Cyclin D1 and EGFR expressions also showed significant (*P* \< 0.05 or *P* \< 0.001) association with site and type of recurrence.

### 3.3.3. Association of marker expressions with time of recurrence {#sec0055}

The association of marker expressions with time of recurrence of 56 recurrent patients is summarized in [Table 6](#tbl0030){ref-type="table"}. The recurrence time of patients ranged from 2--21 months with mean (± SE) 8.59 ± 0.60 months and median 7-months. The expressions of all three markers showed significant association with time of recurrence. On comparing, Student's t test showed significant and early recurrence time in patients with strong positive Cyclin D1 (10.37 ± 0.88 vs. 6.54 ± 0.63, *P* = 0.001) and EGFR (11.32 ± 1.19 vs. 7.19 ± 0.56, *P* = 0.001) expressions as compared to respective positive expressions. Further, ANOVA followed by Tukey post hoc test also showed significant and early mean recurrence time in patients with p53 positive (19.25 ± 0.85 vs. 12.67 ± 0.88, *P* = 0.028) and strong positive (19.25 ± 0.85 vs. 7.47 ± 0.48, *P* \< 0.001) expressions as compared to negative expression. Moreover, the mean recurrence time was also found earlier in patients with p53 strong positive expression as compared to positive expression (12.67 ± 0.88 vs. 7.47 ± 0.48, *P* = 0.025).

3.4. Prognosis of markers {#sec0060}
-------------------------

The follow up (survival) duration of patients ranged from 1--24 month with mean (± SE) 10.84 ± 0.39 months and median 9-months. During the period, 210 (72.4%) patients were alive, 32 (11.0%) lost to follow-up (LTF) and 48 (16.6%) died due to disease accounting total 242 (83.4%) patients live (alive + LTF). Further, at final evaluation, 128 (44.1%) patients were disease free (i.e. CR) and 234 (80.7%) were recurrence free.

To find out prognosis of markers, the associations of markers expressions with overall survival (OS), disease free survival (DFS) and recurrence free survival (RFS) were done using Kaplan-Meier method followed by Log rank test and summarized in [Table 7](#tbl0035){ref-type="table"}, [Table 8](#tbl0040){ref-type="table"}, [Table 9](#tbl0045){ref-type="table"} respectively and [Fig. 2](#fig0010){ref-type="fig"}, [Fig. 3](#fig0015){ref-type="fig"}, [Fig. 4](#fig0020){ref-type="fig"} respectively. The Cyclin D1, EGFR and p53 expressions showed significant (*P* \< 0.001) associations with OS, DFS and RFS and showed poor OS, DFS and RFS survivals in patients with positive/strong positive expressions than negative expression.

3.5. Predictors of overall survival {#sec0065}
-----------------------------------

To find out independent predictors of overall survival, univariate (unadjusted) and multivariate (adjusted) Cox regression analysis was done between survival (survival duration and event) and clinico-pathological characteristics and markers expressions and summarized in [Table 10](#tbl0050){ref-type="table"}. The univariate Cox regression analysis showed significant (*P* \< 0.05 or *P* \< 0.01 or *P* \< 0.001) association of overall survival with performance status, primary site, histological grade, tumor size, node status, stage, radiological response and marker expressions (Cyclin D1, EGFR and p53) suggesting these as predictors of overall survival. The multivariate Cox regression analysis further showed significant (*P* \< 0.05 or *P* \< 0.001) association of overall survival with primary site, radiological response and p53 expression indicating these as significant and an independent predictors of overall survival in OSCC patients.

3.6. Predictors of recurrence {#sec0070}
-----------------------------

The association of recurrence with clinico-pathological characteristics and marker expressions was done using univariate (unadjusted) and multivariate (adjusted) logistic regression analysis and summarized in [Table 11](#tbl0055){ref-type="table"}. The univariate logistic regression analysis showed significant association (*P* \< 0.05 or *P* \< 0.01 or *P* \< 0.001) of primary site, differentiation, node status, response and marker expressions (Cyclin D1, EGFR and p53) with the recurrence. The multivariate logistic regression analysis further showed significant (*P* \< 0.05 or *P* \< 0.01 or *P* \< 0.001) association of recurrence with primary site, differentiation, Cyclin D1 and p53 expressions indicating these significant and an independent risk predictors of recurrence in OSCC patients. Further, the univariate Cox regression analysis showed significant (*P* \< 0.05 or *P* \< 0.01 or *P* \< 0.001) association of recurrence with economic status, histology, histological grade, tumor size, node status, stage and marker expressions (Cyclin D1, EGFR and p53) suggesting these as predictors of recurrence ([Table 12](#tbl0060){ref-type="table"}). The multivariate Cox regression analysis further showed significant (*P* \< 0.05 or *P* \< 0.01) association of recurrence with node status, Cyclin D1 and p53 expressions indicating these as significant and an independent predictors of recurrence in OSCC patients undergoing chemoradiation ([Table 12](#tbl0060){ref-type="table"}).

3.7. Survival of recurrent patients {#sec0075}
-----------------------------------

The time to recurrence survival of recurrent patients according to site and type of recurrence were also evaluated and summarized in [Table 13](#tbl0065){ref-type="table"} and [Fig. 5](#fig0025){ref-type="fig"}. There was no significant difference in the median survival in patients according to site of recurrence (χ^2^ = 7.69, *P* = 0.104). In contrast, the median survival in patients with distant recurrence was found significantly lower as compared to locoregional (χ^2^ = 4.86, *P* = 0.027).

4. Discussion {#sec0080}
=============

Squamous cell carcinoma is by far the most common cancer type of the oral cavity, representing more than 90% of all oral cancer [@bib0110]. The overall survival rates have not improved for more than decades even in major treatment centers inspite of all possible definitive treatment approaches; dreadful and alarming event of locoregional relapse is customary and elucidates for major cause of morbidity and mortality in these patients. This has engendered and entrenched notion to identify molecular biomarkers that accurately predict patients at risk for disease recurrence and treatment resistance. Furthermore identification of biomarkers that would signal increased risk of treatment failure in OSCC would have a major impact on treatment decisions and its outcome [@bib0115]. Despite of tremendous search for prognostic markers, no single molecular study till date has been shown to identify and focus at high risk for recurrences which is the most distressing component of treatment failure in the patients of OSCC [@bib0060]. OSCC pathogenesis is a complex process and thought to arise as a result of multiple molecular events developing from the combined effect of an individual's genetic predisposition and exposure to environmental carcinogens. These genetic alterations includes mutations or amplification of oncogenes as well as inactivation of tumor suppressor genes evident by expression of various molecular markers, leading to tumorogenesis which acquire self sufficient unexceptional growth and escape growth inhibitory signals, making the cells immortal resulting in uncontrolled tumor growth [@bib0115]. Over a period of time and with further exposure to carcinogens, the cancer cells accumulate further mutations and acquire more evil characteristics such as ability to invade and move into adjoining tissues, progress to lymphatics and blood vessels, tumor angiogenesis and may reside and grow to distant sites [@bib0120].

While on conventional treatment regimen or in the post treatment follow up period some cancer cells due to genetic instability may acquire further mutations and become resistant or refractory to the treatment delivered, leading to progression or recurrence of cancer \[[@bib0120], [@bib0125]\]. Moreover cytotoxic treatment regimen which itself is immunosuppressive and generates of lot of stress from cradle to grave might also enhance the odds of risk of tumor recurrence due to ineffective immunosuppressive treatment which is only enabling the immune system of the body to identify and destroy the newly formed tumor cells, when they are few in number [@bib0130]. Hence high mortality rate due to treatment resistance, tumor recurrence and aggressive disease course are the considerable frightening challenges mainly in the storyline of scarcity of resources available with the patients. So at a very critical moment molecular markers had actually mesmerized into conclusion of having significant role in prognosis, prediction of disease course and selection of treatment regimen. Although many molecular markers and tumor markers have been studied and have revolutionized the pathogenesis of head and neck squamous cell carcinoma (HNSCC) still they are not yet ready to be used in routine clinical, investigative and therapeutic procedures in patients with these tumors. Preponderantly tumor stage, patient's age and performance status still remains the basis for therapeutic decisions \[[@bib0110], [@bib0115], [@bib0135], [@bib0140]\]. These all have attributed to the urge of advancement and innovations in research approaches of molecular biology, genomics and proteomics with a tremendous hope at the end of tunnel [@bib0140]. Improvement and development of research procedures would assist to understand more specific and sensitive markers aiding in tumor diagnosis, selection of treatment modality, monitoring of response to therapeutic interventions, early detection of tumor recurrence, prediction of the treatment outcome and identification of subsets of patients with unfavorable outcome during the therapeutic interventions and follow-up period, thereby facilitating to achieve beneficial outcome in terms of response and survival in the patients with these tumors.

The current study has hence being proposed to evaluate expressions and correlation of Cyclin D1, EGFR and p53 with stratification of recurrences in oral cancer patients. Plethora of studies suggesting prognostics of expression of Cyclin D1, EGFR and p53 have been documented in malignancies of head and neck, breast, lung, colorectal, bladder and Gastrointestinal tract, however there has been limited convincing studies on evaluation of risk and pattern of recurrences in oral cancer, wherein timeline evaluation, stratification of the risk and pattern of recurrence is warranted to achieve the substantial and sustainable benefit of delivered treatment \[[@bib0145], [@bib0150]\]. Although some of the studies have documented that p53 mutation can estimates disease prognosis more accurately than clinical staging in HNSCC, and could stratify patients according to their risk of locoregional recurrence but have not reached to a significant conclusion \[[@bib0110], [@bib0145]\]. A prospective study in Chinese patient with laryngeal squamous cell carcinoma concluded that p53, p21 and Cdc2 may be involved in the occurrence, development and recurrence of tumor. It also suggested that combined detection of these three proteins might be a useful parameter for screening patients at high risk of recurrence which is worthy of further molecular studies [@bib0140]. In our study also we found that patients with strong positive p53 expression were associated with early recurrence as compared to moderately positive or negative expression. Some more studies have documented that overexpression of p53 is a potential marker for recurrence of tumor although been proved in various other types of malignancies. In ER-positive breast cancer, p53 accumulation was found to be a strong predictor of both early and late recurrence [@bib0155]. Studies have suggested association of p53 overexpression with high risk for disease recurrence and poor survival in colorectal carcinoma and urothelal cancer \[[@bib0160], [@bib0165]\]. p53 overexpression, has also been found to be a good prognostic marker to predict the risk of local recurrence and distant metastasis in bone tumor \[[@bib0115], [@bib0160], [@bib0170]\]. p53 gene mutation frequently occurs in recurrent ovarian cancer and influences salvage chemotherapy thereby impacting upon the prognosis of recurrent disease [@bib0175]. Studies have cited correlation of EGFR expression with recurrence in rectal and penile cancer but with a limitation of long survival period \[[@bib0180], [@bib0185]\]. In advanced head and neck cancer studies have suggested EGFR as robust predictor of local relapse but failed to predict correlation with distant metastasis [@bib0055]. In the present study we have observed that overexpression of EGFR was related to early recurrence and to a greater extent to distant sites in OSCC patients treated by chemoradiation. Therefore understanding of EGFR expression has a significant implication and can contribute to the identification of patients with an increased risk of recurrences and in targeting treatment for better outcome. Cyclin D1 genetic alteration was found to be an early event in the carcinogenesis of transitional cell carcinoma of bladder and resulted in the rapid recurrence of a subset of superficial bladder cancer [@bib0190]. In esophageal squamous cell carcinoma, there was increased early recurrence of disease in Cyclin D1 overexpressed patients [@bib0195]. Furthermore, Cyclin D1 overexpression has also been found to be associated with tumor aggression, reduced survival and tumor recurrence in HNSCC although mostly studied in different anatomical sites [@bib0060]. In nasopharyngeal carcinoma, early local recurrence rate were significantly higher in patients with high levels of Cyclin D1 evaluated before initiation of radiation therapy when compared with patients with low or no expression [@bib0200]. In fact there are very few convincing studies documented correlating Cyclin D1 expression with the pattern of recurrence in oral cancer patients [@bib0205]. In our study we speculated that patients with overexpression of Cyclin D1 were significantly associated with increased recurrence. Patients with higher expression had more propensities to recur in distant sites along with early time to recurrence as compared to positive/negative expression.

Therefore in view of immense bulk of oral cancer patients in productive years of life and excessively with greater tendency to recur, it would be beneficial to evaluate correlation of these markers with risk and pattern of recurrence so as to select the patients and customize the therapeutic intervention to maximize its benefit in oral cancer. Here we conclude that over expression of Cyclin D1, EGFR and p53 are associated with tumor recurrence, reduced time to recurrence at primary and distant sites. As evident in our study tumors over expressing Cyclin D1, EGFR and p53 are resistant to chemoradiation and expression of these markers might be an indicator of the risk of locoregional recurrence and metastasis in patients of OSCC treated by chemoradiation. Hence, comprehensive and collaborative interpretation of expression of Cyclin D1, EGFR and p53 would contribute to the identification of patients at increased risk of tumor recurrence and further these patients might be benefited from more intensive and targeted treatment regimen. The findings of the present study may be further validated on larger sample size, co expressions of the markers and by evaluation and exploration of respective gene locus and genetic stability which was the limitation of the study.
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![Microphotograph showing Immunohistochemical expression of Cyclin D1 (A) showing negative nuclei (B) showing moderate positive stained nuclei (C) showing strongly positive stained nuclei (DAB × 125 × digital magnification); EGFR (D) showing negative cytoplasmic and membranous staining (E) showing moderate positive cytoplasmic and membranous staining (F) showing strongly positive cytoplasmic and membranous staining (DAB x 125 x digital magnification); p53 (H) showing negative nuclei (I) showing moderate positive stained nuclei (J) showing strongly positive stained nuclei (DAB x 125 x digital magnification) in OSCC.](gr1){#fig0005}

![Overall survival according to marker expressions were compared by Kaplan-Meier method followed by Log rank (Mantel-Cox: χ^2^) test. Marker expressions showed significant association with overall survival in OSCC patients (Cyclin D1: χ^2^ = 49.80, df = 2, *P*\<0.001, EGFR: χ^2^ = 59.95, df = 2, *P* \< 0.001, and p53: χ^2^ = 84.84, df = 2, *P* \< 0.001).](gr2){#fig0010}

![Disease free survival according to marker expressions were compared by Kaplan-Meier method followed by Log rank (Mantel-Cox: χ^2^) test. Marker expressions showed significant association with overall survival in OSCC patients (Cyclin D1: χ^2^ = 68.00, df = 2, *P* \< 0.001, EGFR: χ^2^ = 29.50, df = 2, *P* \< 0.001, and p53: χ^2^ = 19.69, df = 2, *P* \< 0.001).](gr3){#fig0015}

![Recurrence free survival according to marker expressions were compared by Kaplan-Meier method followed by Log rank (Mantel-Cox: χ^2^) test. Marker expressions showed significant association with overall survival in OSCC patients (Cyclin D1: χ^2^ = 124.84, df = 2, *P* \< 0.001, EGFR: χ^2^ = 77.04, df = 2, *P* \< 0.001, and p53: χ^2^ = 106.33, df = 2, *P* \< 0.001).](gr4){#fig0020}

![Time to recurrence survival according to site and type of recurrence were compared by Kaplan-Meier method followed by Log rank (Mantel-Cox: χ^2^) test. Site (χ^2^ = 7.69, df = 4, *P* = 0.104) showed insignificant association while type of recurrence (χ^2^ = 4.86, df = 1, *P* = 0.027) showed significant association with time to recurrence survival in OSCC patients undergoing chemoradiation.](gr5){#fig0025}

###### 

Clinico-pathological characteristics of OSCC patients.

Table 1

  Variables            (n = 290) (%)
  -------------------- ---------------
  Age (yrs)            
   ≤60                 220 (75.9)
   \>60                70 (24.1)
                       
  Sex                  
   Female              59 (20.3)
   Male                231 (79.7)
                       
  Economic status      
   Upper               7 (2.4)
   Middle              111 (38.3)
   Poor                172 (59.3)
                       
  Tobacco chewing      
   No                  98 (33.8)
   Yes                 192 (66.2)
                       
  Betel nut chewing    
   No                  109 (37.6)
   Yes                 181 (62.4)
                       
  Smoking              
   No                  128 (44.1)
   Yes                 162 (55.9)
                       
  Performance status   
   Good                165 (56.9)
   Poor                125 (43.1)
                       
  Primary site         
   Buccal mucosa       93 (32.1)
   Alveolus            45 (15.5)
   Hard palate         38 (13.1)
   Lip                 27 (9.3)
   RMT                 39 (13.4)
   Tongue              48 (16.6)
                       
  Histology            
   SCC                 102 (35.2)
   ISCC                188 (64.8)
                       
  Grade                
   WD                  195 (67.2)
   MD                  77 (26.6)
   PD                  18 (6.2)
                       
  Tumor size           
   T2                  6 (2.1)
   T3                  65 (22.4)
   T4                  219 (75.5)
                       
  Node status          
   N0                  89 (30.7)
   N1                  96 (33.1)
   N2                  105 (36.2)
                       
  Stage                
   III                 62 (21.4)
   IV                  228 (78.6)
                       
  Response             
   CR                  128 (44.1)
   PR                  135 (46.6)
   NR                  27 (9.3)

SCC: squamous cell carcinoma, ISCC: invasive squamous cell carcinoma, WD: well differentiated, MD: moderately differentiated, PD: poorly differentiated, CR: complete response, PR: partial response, NR: no response.

###### 

Marker expressions of OSCC patients.

Table 2

  Marker expression   (n = 290) (%)
  ------------------- ---------------
  Cyclin D1           
   Negative           31 (10.7)
   Positive           197 (67.9)
   Strong positive    62 (21.4)
                      
  EGFR                
   Negative           13 (4.5)
   Positive           135 (46.6)
   Strong positive    142 (49.0)
                      
  p53                 
   Negative           35 (12.1)
   Positive           46 (15.9)
   Strong positive    209 (72.1)

###### 

Association of marker expressions with clinico-pathological characteristics in OSCC patients (n = 290).

Table 3

  Variables           n(%)   Cyclin D1 expression   EGFR expression   p53 expression                                                                                                         
  ------------------- ------ ---------------------- ----------------- ---------------- ------------- ---------- ------------ ------------ ------------- ----------- ----------- ------------ -------------
  Age (yrs)                                                                                                                                                                                  
   ≤60                220    25 (11.4)              142 (64.5)        53 (24.1)        0.080         12 (5.5)   96 (43.6)    112 (50.9)   0.117         30 (13.6)   27 (12.3)   163 (74.1)   **0.008**
   \>60               70     6 (8.6)                55 (78.6)         9 (12.9)                       1 (1.4)    39 (55.7)    30 (42.9)                  5 (7.1)     19 (27.1)   46 (65.7)    
                                                                                                                                                                                             
  Sex                                                                                                                                                                                        
   Female             59     8 (13.6)               45 (76.3)         6 (10.2)         0.058         5 (8.5)    30 (50.8)    24 (40.7)    0.138         10 (16.9)   10 (16.9)   39 (66.1)    0.390
   Male               231    23 (10.0)              152 (65.8)        56 (24.2)                      8 (3.5)    105 (45.5)   118 (51.1)                 25 (10.8)   36 (15.6)   170 (73.6)   
                                                                                                                                                                                             
  Economic status                                                                                                                                                                            
   Upper/Middle       118    12 (10.2)              79 (66.9)         27 (22.9)        0.866         1 (0.8)    63 (53.4)    54 (45.8)    **0.016**     15 (12.7)   19 (16.1)   84 (71.2)    0.953
   Poor               172    19 (11.0)              118 (68.6)        35 (20.3)                      12 (7.0)   72 (41.9)    88 (51.2)                  20 (11.6)   27 (15.7)   125 (72.7)   
                                                                                                                                                                                             
  Tobacco chewing                                                                                                                                                                            
   No                 98     7 (7.1)                66 (67.3)         25 (25.5)        0.231         7 (7.1)    37 (37.8)    54 (55.1)    0.051         9 (9.2)     10 (10.2)   79 (80.6)    0.064
   Yes                192    24 (12.5)              131 (68.2)        37 (19.3)                      6 (3.1)    98 (51.0)    88 (45.8)                  26 (13.5)   36 (18.8)   130 (67.7)   
                                                                                                                                                                                             
  Betel nut chewing                                                                                                                                                                          
   No                 109    11 (10.1)              73 (67.0)         25 (22.9)        0.869         7 (6.4)    43 (39.4)    59 (54.1)    0.116         12 (11.0)   14 (12.8)   83 (76.1)    0.457
   Yes                181    20 (11.0)              124 (68.5)        37 (20.4)                      6 (3.3)    92 (50.8)    83 (45.9)                  23 (12.7)   32 (17.7)   126 (69.6)   
                                                                                                                                                                                             
  Smoking                                                                                                                                                                                    
   No                 128    13 (10.2)              95 (74.2)         20 (15.6)        0.084         7 (5.5)    58 (45.3)    63 (49.2)    0.750         21 (16.4)   16 (12.5)   91 (71.1)    0.073
   Yes                162    18 (11.1)              102 (63.0)        42 (25.9)                      6 (3.7)    77 (47.5)    79 (48.8)                  14 (8.6)    30 (18.5)   118 (72.8)   
                                                                                                                                                                                             
  PS                                                                                                                                                                                         
   Good               165    21 (12.7)              117 (70.9)        27 (16.4)        **0.039**     8 (4.8)    86 (52.1)    71 (43.0)    0.067         26 (15.8)   29 (17.6)   110 (66.7)   0.037
   Poor               125    10 (8.0)               80 (64.0)         35 (28.0)                      5 (4.0)    49 (39.2)    71 (56.8)                  9 (7.2)     17 (13.6)   99 (79.2)    
                                                                                                                                                                                             
  Primary site                                                                                                                                                                               
   Buccal mucosa      93     8 (8.6)                67 (72.0)         18 (19.4)        0.560         5 (5.4)    34 (36.6)    54 (58.1)    0.064         3 (3.2)     8 (8.6)     82 (88.2)    \<0.001
   Other              197    23 (11.7)              130 (66.0)        44 (22.3)                      8 (4.1)    101 (51.3)   88 (44.7)                  32 (16.2)   38 (19.3)   127 (64.5)   
                                                                                                                                                                                             
  Histology                                                                                                                                                                                  
   SCC                102    6 (5.9)                76 (74.5)         20 (19.6)        0.099         2 (2.0)    53 (52.0)    47 (46.1)    0.175         13 (12.7)   20 (19.6)   69 (67.6)    0.391
   ISCC               188    25 (13.3)              121 (64.4)        42 (22.3)                      11 (5.9)   82 (43.6)    95 (50.5)                  22 (11.7)   26 (13.8)   140 (74.5)   
                                                                                                                                                                                             
  Grade                                                                                                                                                                                      
   WD                 195    31 (15.9)              149 (76.4)        15 (7.7)         **\<0.001**   13 (6.7)   106 (54.4)   76 (39.0)    **\<0.001**   34 (17.4)   46 (23.6)   115 (59.0)   **\<0.001**
   MD/PD              95     0 (0.0)                48 (50.5)         47 (49.5)                      0 (0.0)    29 (30.5)    66 (69.5)                  1 (1.1)     0 (0.0)     94 (98.9)    
                                                                                                                                                                                             
  Tumor size                                                                                                                                                                                 
   T2/T3              71     14 (19.7)              48 (67.6)         9 (12.7)         **0.005**     4 (5.6)    41 (57.7)    26 (36.6)    0.057         17 (23.9)   19 (26.8)   35 (49.3)    **\<0.001**
   T4                 219    17 (7.8)               149 (68.0)        53 (24.2)                      9 (4.1)    94 (42.9)    116 (53.0)                 18 (8.2)    27 (12.3)   174 (79.5)   
                                                                                                                                                                                             
  Node status                                                                                                                                                                                
   N0                 89     16 (18.0)              69 (77.5)         4 (4.5)          **\<0.001**   8 (9.0)    58 (65.2)    23 (25.8)    **\<0.001**   18 (20.2)   25 (28.1)   46 (51.7)    **\<0.001**
   N1/N2              201    15 (7.5)               128 (63.7)        58 (28.9)                      5 (2.5)    77 (38.3)    119 (59.2)                 17 (8.5)    21 (10.4)   163 (81.1)   
                                                                                                                                                                                             
  Stage                                                                                                                                                                                      
   III                62     14 (22.6)              45 (72.6)         3 (4.8)          **\<0.001**   4 (6.5)    39 (62.9)    19 (30.6)    **0.005**     17 (27.4)   19 (30.6)   26 (41.9)    **\<0.001**
   IV                 228    17 (7.5)               152 (66.7)        59 (25.9)                      9 (3.9)    96 (42.1)    123 (53.9)                 18 (7.9)    27 (11.8)   183 (80.3)   
                                                                                                                                                                                             
  Response                                                                                                                                                                                   
   CR/PR              263    31 (11.8)              197 (74.9)        25 (13.3)        **\<0.001**   13 (4.9)   135 (51.3)   115 (43.7)   \<0.001       35 (13.3)   46 (17.5)   182 (69.2)   **0.003**
   NR                 27     0 (0.0)                0 (0.0)           27 (100.0)                     0 (0.0)    0 (0.0)      27 (100.0)                 0 (0.0)     0 (0.0)     27 (100.0)   

Bold values are highly significant.

###### 

Association of marker expressions with clinico-pathological characteristics in OSCC patients using multivariate logistic regression analysis (n = 290).

Table 4

  Variables           Cyclin D1 expression   EGFR expression   p53 expression                                       
  ------------------- ---------------------- ----------------- ------------------- ----------- -------------------- -----------
  Age (yrs)                                                                                                         
   ≤60                Ref                                      Ref                             Ref                  
   \>60               1.09 (0.30--3.99)      0.902             1.03 (0.54--1.97)   0.928       0.16 (0.48--2.34)    **0.014**
                                                                                                                    
  Sex                                                                                                               
   Female             Ref                                      Ref                             Ref                  
   Male               0.27 (0.04--1.73)      0.168             0.59 (0.25--1.40)   0.234       1.24 (0.38--4.01)    0.718
                                                                                                                    
  Economic status                                                                                                   
   Upper/Middle       Ref                                      Ref                             Ref                  
   Poor               1.09 (0.34--3.45)      0.887             0.98 (0.55--1.74)   0.932       1.57 (0.73--3.35)    0.247
                                                                                                                    
  Tobacco chewing                                                                                                   
   No                 Ref                                      Ref                             Ref                  
   Yes                4.96 (0.91--22.84)     **0.039**         1.22 (0.40--3.72)   0.724       8.92 (2.32--34.28)   **0.001**
                                                                                                                    
  Betel nut chewing                                                                                                 
   No                 Ref                                      Ref                             Ref                  
   Yes                0.03 (0.00--1.51)      0.078             0.97 (0.31--3.04)   0.955       0.21 (0.05--0.86)    **0.031**
                                                                                                                    
                                                                                                                    
  Smoking                                                                                                           
   No                 Ref                                      Ref                             Ref                  
   Yes                3.00 (0.57--15.82)     0.195             1.59 (0.73--3.48)   0.243       1.47 (0.54--3.74)    0.470
                                                                                                                    
  PS                                                                                                                
   Good               Ref                                      Ref                             Ref                  
   Poor               0.94 (0.31--2.82)      0.912             0.70 (0.40--1.23)   0.217       0.70 (0.32--1.50)    0.355
                                                                                                                    
  Primary site                                                                                                      
   Buccal mucosa      Ref                                      Ref                             Ref                  
   Other              0.34 (0.09--1.34)      0.122             1.57 (0.88--2.80)   0.126       4.96 (1.90--13.04)   **0.001**
                                                                                                                    
  Histology                                                                                                         
   SCC                Ref                                      Ref                             Ref                  
   ISCC               2.82 (0.67--11.95)     0.159             0.88 (0.48--1.61)   0.675       1.09 (0.51--2.31)    0.833
                                                                                                                    
  Grade                                                                                                             
   WD                 Ref                                      Ref                             Ref                  
   MD/PD              0.02 (0.00--0.15)      **\<0.001**       0.42 (0.22--0.81)   **0.009**   0.03 (0.00--0.24)    **0.001**
                                                                                                                    
  Tumor size                                                                                                        
   T2/T3              Ref                                      Ref                             Ref                  
   T4                 3.50 (0.69--17.41)     **0.043**         1.37 (0.22--8.62)   0.735       4.84 (0.69--12.17)   **0.046**
                                                                                                                    
  Node status                                                                                                       
   N0                 Ref                                      Ref                             Ref                  
   N1/N2              0.29 (0.04--1.93)      **0.020**         0.33 (0.17--0.64)   **0.001**   0.31 (0.14--0.69)    **0.004**
                                                                                                                    
  Stage                                                                                                             
   III                Ref                    **0.031**         Ref                 0.275       Ref                  **0.040**
   IV                 0.01 (0.00--0.87)                        0.35 (0.05--2.30)               0.02 (0.00--0.25)    
                                                                                                                    
  Response                                                                                                          
   CR/PR              Ref                                      Ref                             Ref                  
   NR                 NA                     --                NA                  --          NA                   --

NA: not applicable.

Bold values are highly significant.

###### 

Association of marker expressions with recurrence, site of recurrence and type of recurrence in OSCC patients.

Table 5

  Variables            n     Cyclin D1 expression   EGFR expression   p53 expression                                                                                                       
  -------------------- ----- ---------------------- ----------------- ---------------- ------------- ---------- ------------ ------------ ----------- ----------- ----------- ------------ -------
  Recurrence                                                                                                                                                                               
   No                  234   31 (13.2)              167 (71.4)        36 (15.4)        **\<0.001**   13 (5.6)   116 (49.6)   105 (44.9)   **0.008**   31 (13.2)   43 (18.4)   160 (68.4)   0.014
   Yes                 56    0 (0.0)                30 (53.6)         26 (46.4)                      0 (0.0)    19 (33.9)    37 (66.1)                4 (7.1)     3 (5.4)     49 (87.5)    
                                                                                                                                                                                           
  Site of recurrence                                                                                                                                                                       
   Bone                3     0 (0.0)                0 (0.0)           3 (100.0)        **0.007**     0 (0.0)    0 (0.0)      3 (100.0)    **0.032**   0 (0.0)     0 (0.0)     3 (100.0)    0.904
   Brain               1     0 (0.0)                0 (0.0)           1 (100.0)                      0 (0.0)    0 (0.0)      1 (100.0)                0 (0.0)     0 (0.0)     1 (100.0)    
   Lung                5     0 (0.0)                0 (0.0)           5 (100.0)                      0 (0.0)    0 (0.0)      5 (100.0)                0 (0.0)     0 (0.0)     5 (100.0)    
   Nodal               31    0 (0.0)                22 (71.0)         9 (29.0)                       0 (0.0)    16 (51.6)    15 (48.4)                3 (9.7)     1 (3.2)     27 (87.1)    
   Primary             16    0 (0.0)                8 (50.0)          8 (50.0)                       0 (0.0)    3 (18.8)     13 (81.3)                1 (6.3)     2 (12.5)    13 (81.3)    
                                                                                                                                                                                           
  Type of recurrence                                                                                                                                                                       
   Locoregional        47    0 (0.0)                30 (63.8)         17 (36.2)        **\<0.001**   0 (0.0)    19 (40.4)    28 (59.6)    **0.019**   4 (8.5)     3 (6.4)     40 (85.1)    0.465
   Distant             9     0 (0.0)                0 (0.0)           9 (100.0)                      0 (0.0)    0 (0.0)      9 (100.0)                0 (0.0)     0 (0.0)     9 (100.0)    

Bold values are highly significant.

###### 

Correlation between marker expression and time of recurrence (month) of OSCC patients (n = 56).

Table 6

  Marker expression   n    Mean ± SE      t/F value   *P* value
  ------------------- ---- -------------- ----------- -------------
  Cyclin D1                                           
   Negative           0    --                         
   Positive           30   10.37 ± 0.88   3.46        **0.001**
   Strong positive    26   6.54 ± 0.62                
                                                      
  EGFR                                                
   Negative           0    --                         
   Positive           19   11.32 ± 1.19   3.58        **0.001**
   Strong positive    37   7.19 ± 0.56                
                                                      
  p53                                                 
   Negative           4    19.25 ± 0.85   26.90       **\<0.001**
   Positive           3    12.67 ± 0.88               
   Strong positive    49   7.47 ± 0.48                

Bold values are highly significant.

###### 

Association of marker expression with overall survival of OSCC patients using Kaplan-Meier survival analysis (n = 290).

Table 7

  Marker expression   n     Mean    Median   χ^2^ value     *P* value                                 
  ------------------- ----- ------- -------- -------------- ----------- ------ -------------- ------- -------------
  Cyclin D1                                                                                           
   Negative           31    13.87   1.40     11.12--16.62   15.00       3.96   7.24--22.76    49.80   **\<0.001**
   Positive           197   11.86   0.46     10.95--12.77   9.00        0.41   8.19--9.81             
   Strong positive    62    6.10    0.50     5.12--7.08     6.00        1.03   3.99--8.01             
                                                                                                      
  EGFR                                                                                                
   Negative           13    14.69   2.15     10.47--18.91   18.00       2.50   13.11--22.89   59.95   **\<0.001**
   Positive           135   13.82   0.60     12.64--15.00   12.00       2.05   7.98--16.02            
   Strong positive    142   7.66    0.38     6.92--8.41     8.00        0.37   7.27--8.73             
                                                                                                      
  p53                                                                                                 
   Negative           35    17.49   1.15     15.24--19.74   19.00       0.98   17.08--20.93   84.84   **\<0.001**
   Positive           46    17.37   0.89     15.62--19.12   18.00       0.68   16.67--19.33           
   Strong positive    209   8.30    0.34     7.64--8.96     7.00        0.31   6.40--7.60             

Bold values are highly significant.

###### 

Association of marker expression with disease free survival of OSCC patients using Kaplan-Meier survival analysis (n = 128).

Table 8

  Marker expression   n    Mean    Median   χ^2^ value     *P* value                                 
  ------------------- ---- ------- -------- -------------- ----------- ------ -------------- ------- -------------
  Cyclin D1                                                                                          
   Negative           18   18.94   1.45     16.10--21.79   21.00       0.69   19.65--22.35   68.00   **\<0.001**
   Positive           84   17.64   0.62     16.43--18.86   18.00       0.42   17.19--18.81           
   Strong positive    26   9.96    0.37     9.23--10.70    10.00       0.63   8.77--11.23            
                                                                                                     
  EGFR                                                                                               
   Negative           11   16.55   2.06     12.52--20.57   18.00       1.06   15.92--20.09   29.50   **\<0.001**
   Positive           80   18.24   0.63     17.01--19.46   19.00       0.56   17.91--20.09           
   Strong positive    37   11.92   0.77     10.40--13.44   11.00       0.53   9.97--12.04            
                                                                                                     
  p53                                                                                                
   Negative           33   18.30   1.05     16.24--20.37   19.00       0.96   17.12--20.88   19.69   **\<0.001**
   Positive           39   18.77   0.84     17.11--20.42   19.00       0.94   17.17--20.84           
   Strong positive    56   13.32   0.73     11.89--14.76   11.00       0.62   9.78--12.22            

Bold values are highly significant.

###### 

Association of marker expression with recurrence free survival of OSCC patients using Kaplan-Meier survival analysis (n = 234).

Table 9

  Marker expression   n     Mean    Median   χ^2^ value     *P* value                                  
  ------------------- ----- ------- -------- -------------- ----------- ------ -------------- -------- -------------
  Cyclin D1                                                                                            
   Negative           31    13.87   1.40     11.12--16.62   15.00       3.96   7.24--22.76    124.84   **\<0.001**
   Positive           167   11.05   0.49     10.09--12.02   8.00        0.37   7.28--8.72              
   Strong positive    36    3.31    0.38     2.56--4.05     3.00        0.22   2.58--3.43              
                                                                                                       
  EGFR                                                                                                 
   Negative           13    14.69   2.15     10.47--18.91   18.00       2.50   13.11--22.89   77.04    **\<0.001**
   Positive           116   13.42   0.66     12.12--14.72   10.00       1.61   6.84--13.16             
   Strong positive    105   6.16    0.33     5.52--6.81     6.00        0.32   5.38--6.63              
                                                                                                       
  p53                                                                                                  
   Negative           31    17.58   1.26     15.11--20.05   19.00       1.11   16.82--21.18   106.33   **\<0.001**
   Positive           43    17.21   0.95     15.35--19.07   18.00       0.73   16.57--19.43            
   Strong positive    160   6.94    0.30     6.34--7.53     7.00        0.20   6.61--7.39              

Bold values are highly significant.

###### 

Predictors of overall survival of OSCC patients using Cox-regression analysis (n = 290).

Table 10

  Predictors           Univariate          Multivariate                       
  -------------------- ------------------- -------------- ------------------- -------------
  Age (yrs)                                                                   
   ≤60                 Ref                                Ref                 
   \>60                1.22 (0.94--1.60)   0.142          1.01 (0.74--1.36)   0.972
                                                                              
  Sex                                                                         
   Female              Ref                                Ref                 
   Male                0.96 (0.72--1.28)   0.793          1.09 (0.75--1.60)   0.657
                                                                              
  Economic status                                                             
   Upper/Middle        Ref                                Ref                 
   Poor                0.91 (0.72--1.15)   0.409          1.19 (0.92--1.54)   0.194
                                                                              
  Tobacco chewing                                                             
   No                  Ref                                Ref                 
   Yes                 1.26 (0.99--1.61)   0.065          0.92 (0.59--1.43)   0.701
                                                                              
  Betel nut chewing                                                           
   No                  Ref                                Ref                 
   Yes                 1.24 (0.97--1.57)   0.085          1.22 (0.75--1.97)   0.426
                                                                              
  Smoking                                                                     
   No                  Ref                                Ref                 
   Yes                 0.96 (0.76--1.21)   0.724          0.93 (0.65--1.32)   0.668
                                                                              
  Performance status                                                          
   Good                Ref                                Ref                 
   Poor                0.75 (0.60--0.95)   **0.017**      0.87 (0.67--1.12)   0.273
                                                                              
  Primary site                                                                
   Buccal mucosa       Ref                                Ref                 
   Other               1.59 (1.23--2.04)   **\<0.001**    1.33 (1.01--1.75)   **0.044**
                                                                              
  Histology                                                                   
   SCC                 Ref                                Ref                 
   ISCC                0.82 (0.64--1.05)   0.123          0.90 (0.69--1.17)   0.437
                                                                              
  Grade                                                                       
   WD                  Ref                                Ref                 
   MD/PD               0.62 (0.48--0.80)   **\<0.001**    1.15 (0.82--1.62)   0.415
                                                                              
  Tumor size                                                                  
   T2/T3               Ref                                Ref                 
   T4                  0.75 (0.57--0.98)   **0.037**      0.67 (0.31--1.43)   0.300
                                                                              
  Node status                                                                 
   N0                  Ref                                Ref                 
   N1/N2               0.62 (0.48--0.80)   **\<0.001**    0.94 (0.69--1.29)   0.717
                                                                              
  Stage                                                                       
   III                 Ref                                Ref                 
   IV                  0.68 (0.51--0.90)   **0.007**      1.48 (0.66--3.32)   0.340
                                                                              
  Response                                                                    
   CR/PR               Ref                                Ref                 
   NR                  0.02 (0.01--0.04)   **\<0.001**    0.03 (0.01--0.07)   **\<0.001**
                                                                              
  Cyclin D1                                                                   
   Negative            Ref                                Ref                 
   Positive            0.31 (0.20--0.49)   **\<0.001**    0.93 (0.49--1.76)   0.819
   Strong positive     0.40 (0.29--0.54)   **\<0.001**    0.86 (0.54--1.38)   0.536
                                                                              
  EGFR                                                                        
   Negative            Ref                                Ref                 
   Positive            0.40 (0.22--0.70)   **0.002**      0.96 (0.49--1.87)   0.894
   Strong positive     0.43 (0.33--0.55)   **\<0.001**    0.86 (0.61--1.21)   0.384
                                                                              
  p53                                                                         
   Negative            Ref                                Ref                 
   Positive            0.32 (0.22--0.46)   **\<0.001**    0.36 (0.21--0.60)   **\<0.001**
   Strong positive     0.34 (0.25--0.48)   **\<0.001**    0.39 (0.25--0.61)   **\<0.001**

Bold values are highly significant.

###### 

Association of recurrence with clinico-pathological characteristics in OSCC patients using logistic regression analysis (n = 290).

Table 11

  Predictors             Recurrence   Univariate   Multivariate                                           
  ---------------------- ------------ ------------ ------------------- ------------- -------------------- -------------
  Age (yrs)                                                                                               
   ≤60                   176 (75.2)   44 (78.6)    Ref                               Ref                  
   \>60                  58 (24.8)    12 (21.4)    1.21 (0.60--2.44)   0.598         0.95 (0.40--2.25)    0.899
                                                                                                          
  Sex                                                                                                     
   Female                45 (19.2)    14 (25.0)    Ref                               Ref                  
   Male                  189 (80.8)   42 (75.0)    1.40 (0.71--2.78)   0.337         2.18 (0.68--7.02)    0.191
                                                                                                          
  Economic status                                                                                         
   Upper/Middle          97 (41.5)    21 (37.5)    Ref                               Ref                  
   Poor                  137 (58.5)   35 (62.5)    0.85 (0.47--1.55)   0.589         0.59 (0.28--1.23)    0.159
                                                                                                          
  Tobacco chewing                                                                                         
   No                    76 (32.5)    22 (39.3)    Ref                               Ref                  
   Yes                   158 (67.5)   34 (60.7)    1.35 (0.74--2.46)   0.334         0.66 (0.10--4.44)    0.673
                                                                                                          
  Betel nut chewing                                                                                       
   No                    85 (36.3)    24 (42.9)    Ref                               Ref                  
   Yes                   149 (63.7)   32 (57.1)    1.32 (0.73--2.38)   0.365         1.26 (0.18--8.94)    0.817
                                                                                                          
  Smoking                                                                                                 
   No                    101 (43.2)   27 (48.2)    Ref                               Ref                  
   Yes                   133 (56.8)   29 (51.8)    1.23 (0.68--2.20)   0.494         1.29 (0.46--3.62)    0.629
                                                                                                          
  Performance status                                                                                      
   Good                  136 (58.1)   29 (51.8)    Ref                               Ref                  
   Poor                  98 (41.9)    27 (48.2)    0.77 (0.43--1.39)   0.391         1.51 (0.74--3.11)    0.262
                                                                                                          
  Primary site                                                                                            
   Buccal mucosa         83 (35.5)    10 (17.9)    Ref                               Ref                  
   Other                 151 (64.5)   46 (82.1)    0.40 (0.19--0.82)   **0.013**     0.21 (0.09--0.54)    **0.001**
                                                                                                          
  Histology                                                                                               
   SCC                   84 (35.9)    18 (32.1)    Ref                               Ref                  
   ISCC                  150 (64.1)   38 (67.9)    0.85 (0.45--1.57)   0.597         1.31 (0.58--2.95)    0.523
                                                                                                          
  Grade                                                                                                   
   WD                    178 (76.1)   17 (30.4)    Ref                               Ref                  
   MD/PD                 56 (23.9)    39 (69.6)    0.14 (0.07--0.26)   **\<0.001**   0.15 (0.06--0.37)    **\<0.001**
                                                                                                          
  Tumor size                                                                                              
   T2/T3                 61 (26.1)    10 (17.9)    Ref                               Ref                  
   T4                    173 (73.9)   46 (82.1)    0.62 (0.29--1.30)   0.202         3.01 (0.38--24.08)   0.300
                                                                                                          
  Node status                                                                                             
   N0                    83 (35.5)    6 (10.7)     Ref                               Ref                  
   N1/N2                 151 (64.5)   50 (89.3)    0.22 (0.09--0.53)   **0.001**     0.47 (0.17--1.32)    0.152
                                                                                                          
  Stage                                                                                                   
   III                   55 (23.5)    7 (12.5)     Ref                               Ref                  
   IV                    179 (76.5)   49 (87.5)    0.47 (0.20--1.09)   0.077         0.30 (0.03--2.72)    0.287
                                                                                                          
  Cyclin D1 expression                                                                                    
   Negative              31 (13.2)    0 (0.0)      Ref                               Ref                  
   Positive              167 (71.4)   30 (53.6)    NA                  --            NA                   --
   Strong positive       36 (15.4)    26 (46.4)    0.25 (0.13--0.47)   **\<0.001**   0.34 (0.26--1.57)    **0.033**
                                                                                                          
  EGFR expression                                                                                         
   Negative              13 (5.6)     0 (0.0)      Ref                               Ref                  
   Positive              116 (49.6)   19 (33.9)    NA                  --            NA                   --
   Strong positive       105 (44.9)   37 (66.1)    0.47 (0.25--0.86)   **0.014**     0.76 (0.30--1.94)    **0.567**
                                                                                                          
  p53 expression                                                                                          
   Negative              31 (13.2)    4 (7.1)      Ref                               Ref                  
   Positive              43 (18.4)    3 (5.4)      0.42 (0.14--1.25)   0.120         1.89 (0.39--9.20)    0.430
   Strong positive       160 (68.4)   49 (87.5)    0.23 (0.07--0.77)   **0.007**     0.29 (0.15--3.71)    **0.019**

NA: not applicable.

Bold values are highly significant.

###### 

Predictors of recurrence of OSCC patients using Cox regression analysis (n = 56).

Table 12

  Predictors             Univariate          Multivariate                        
  ---------------------- ------------------- -------------- -------------------- -----------
  Age (yrs)                                                                      
   ≤60                   Ref                                Ref                  
   \>60                  1.01 (0.53--1.95)   0.968          0.95 (0.44--2.05)    0.903
                                                                                 
  Sex                                                                            
   Female                Ref                                Ref                  
   Male                  0.65 (0.33--1.27)   0.204          0.82 (0.24--2.82)    0.758
                                                                                 
  Economic status                                                                
   Upper/Middle          Ref                                Ref                  
   Poor                  1.65 (0.94--2.88)   **0.040**      1.59 (0.71--3.57)    0.263
                                                                                 
  Tobacco chewing                                                                
   No                    Ref                                Ref                  
   Yes                   0.82 (0.46--1.45)   0.488          1.11 (0.18--6.92)    0.912
                                                                                 
  Betel nut chewing                                                              
   No                    Ref                                Ref                  
   Yes                   0.75 (0.43--1.31)   0.309          0.98 (0.13--7.59)    0.984
                                                                                 
  Smoking                                                                        
   No                    Ref                                Ref                  
   Yes                   0.74 (0.42--1.29)   0.287          1.15 (0.42--3.18)    0.787
                                                                                 
  Performance status                                                             
   Good                  Ref                                Ref                  
   Poor                  0.66 (0.38--1.14)   0.131          0.86 (0.39--1.89)    0.705
                                                                                 
  Primary site                                                                   
   Buccal mucosa         Ref                                Ref                  
   Other                 1.29 (0.64--2.59)   0.475          0.83 (0.33--2.07)    0.689
                                                                                 
  Histology                                                                      
   SCC                   Ref                                Ref                  
   ISCC                  0.53 (0.29--0.95)   **0.033**      0.54 (0.23--1.27)    0.159
                                                                                 
  Grade                                                                          
   WD                    Ref                                Ref                  
   MD/PD                 0.43 (0.23--0.81)   **0.009**      1.61 (0.54--4.83)    0.392
                                                                                 
  Tumor size                                                                     
   T2/T3                 Ref                                Ref                  
   T4                    0.42 (0.19--0.94)   **0.035**      1.18 (0.25--5.61)    0.836
                                                                                 
  Node status                                                                    
   N0                    Ref                                Ref                  
   N1/N2                 0.16 (0.05--1.09)   **\<0.001**    0.06 (0.02--3.67)    **0.003**
  Stage:                                                                         
   III                   Ref                                Ref                  
   IV                    0.24 (0.09--0.68)   **0.007**      1.27 (0.14--11.62)   0.835
                                                                                 
  Cyclin D1 expression                                                           
   Negative/Positive     Ref                                Ref                  
   Strong positive       0.41 (0.23--0.73)   **0.002**      0.34 (0.12--0.99)    **0.048**
                                                                                 
  EGFR expression                                                                
   Negative/Positive     Ref                                Ref                  
   Strong positive       0.42 (0.23--0.77)   **0.005**      1.31 (0.50--3.45)    0.586
                                                                                 
  p53 expression                                                                 
   Negative/Positive     Ref                                Ref                  
   Strong positive       0.16 (0.06--0.47)   **0.001**      0.09 (0.02--0.49)    **0.006**

Bold values are highly significant.

###### 

Time to recurrence survival of OSCC patients according to site and type of recurrence using Kaplan-Meier survival analysis (n = 234).

Table 13

  Survival-Recurrent patients   n    Mean    Median   χ^2^ value    p value                               
  ----------------------------- ---- ------- -------- ------------- --------- ------ ------------- ------ -----------
  Site of recurrence                                                                                      
  Bone                          3    7.33    0.67     6.03--8.64    8.00      0.00   NA            7.69   0.104
  Brain                         1    6.00    0.00     6.00--6.00    6.00      NA     NA                   
  Lung                          5    5.20    1.07     3.11--7.29    5.00      1.10   2.85--7.15           
  Nodal                         31   8.58    0.76     7.09--10.07   7.00      0.80   5.44--8.56           
  Primary                       16   10.06   1.38     7.36--12.77   7.00      6.00   0.00--18.76          
                                                                                                          
  Type of recurrence                                                                                      
  Locoregional                  47   9.09    0.69     7.74--10.43   7.00      0.86   5.32--8.68    4.86   **0.027**
  Distant                       9    6.00    0.69     4.65--7.35    6.00      0.75   4.54--7.46           

NA: not applicable.

Bold values are highly significant.
